本文已被：浏览 2410次 下载 2次
中文摘要: 目的 对绝经后老年骨质疏松症患者给予唑来膦酸钠治疗，分析其临床效果。方法 选取2016年5月—2017年5月医院收治的绝经后老年骨质疏松症患者80例，将其随机分为观察组（n=40）与对照组（n=40）。给予对照组患者维生素D、钙制剂以及口服阿仑膦酸钠治疗，给予观察组维生素D、钙制剂以及唑来膦酸钠治疗，对两组治疗前后腰椎骨密度、VAS评分及不良反应等进行观察与比较。结果 在股骨颈、腰椎和Ward's三角区骨密度方面，两组治疗6个月、12个月后均较治疗前明显升高，而与对照组比较，观察组治疗后腰椎骨密度改善更显著，差异具有统计学意义（P＜0.05）；与治疗前比较，两组患者治疗后血钙、血磷、PTH及N-MID水平均无明显变化，差异无统计学意义（P＞0.05）；与治疗前相比，观察组CT、25(OH)VD含量明显升高，β-CTx以及ICTP含量明显降低，差异具有统计学意义（P＜0.05）；对照组上述各指标治疗前后无统计学意义（P＞0.05）。在VAS评分方面，两组治疗后均较治疗前明显降低，而与对照组比较，观察组治疗后VAS评分改善更显著，差异具有统计学意义（P＜0.05）；在不良反应发生率方面，观察组与对照组比较无明显变化，差异无统计学意义（P＞0.05）。结论 对绝经后老年骨质疏松症患者给予唑来膦酸钠治疗能够使患者的骨密度明显增加，使患者VAS疼痛评分，能够显著改善CT、25(OH)VD、β-CTx以及ICTP含量，且临床疗效安全可靠，值得临床上应用与推广。
Abstract:OBJECTIVE To treat patients with osteoporosis in postmenopausal women with zoledronic acid and to analyze their clinical effect. METHODS Eighty patients with postmenopausal osteoporosis were selected from May 2016 to May 2017, and were randomly divided into observation group (n = 40) and control group (n = 40). The patients in the control group were treated with vitamin D, calcium preparations and oral alendronate. The patients were treated with vitamin D, calcium preparations and sodium zoledronic acid. The bone density, VAS score and adverse reactions were measured before and after treatment. Observation and comparison. RESULTS In the femoral neck, lumbar vertebrae and Ward's triangular bone density, the two groups were treated for 6 months and 12 months later, respectively. Compared with the control group, the bone density of the lumbar vertebra after treatment was more significant and different (P <0.05). Compared with before treatment, there was no significant difference in serum calcium, phosphorus and PTH between the two groups (P> 0.05). Compared with before treatment, (P <0.05). There was no significant difference between the two groups (P> 0.05). There was no significant difference between the two groups (P> 0.05). The level of CT and 25 (OH) VD in the observation group was significantly higher than that in the control group (P> 0.05). In the VAS score, the two groups were significantly lower than before treatment, and compared with the
control group, the observation group after treatment VAS score improved more significant differences were statistically significant (P <0.05); in the incidence of adverse reactions, There was no significant difference between the observation group and the control group (P> 0.05).CONCLUSION Treatment of postmenopausal osteoporosis patients with zoledronic acid can significantly increase the bone mineral density of patients, so that patients with VAS pain score, can significantly improve the CT, 25 (OH) VD, β-CTx and ICTP content, and Clinical efficacy of safe and reliable, worthy of clinical application and promotion.
文章编号：3201711022 中图分类号：R681 文献标志码：
基金项目:
引用文本：